ArticleAmerican journal of translational research2012
An exploratory clinical trial for combination wound therapy with a novel medical matrix and fibroblast growth factor in patients with chronic skin ulcers: a study protocol.
Article in American journal of translational research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Protease-modulating matrix treatments for healing venous leg ulcers.The Cochrane database of systematic reviews · 2016Pooled it
- [Prospective randomized controlled study on clinical effects of autologous skin paste in repairing medium-thickness skin donor site wounds].Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns · 2021Trial
- Concomitant heparin use promotes skin graft donor site healing by basic fibroblast growth factor: A pilot prospective randomized controlled study.Contemporary clinical trials communications · 2024Article
- Bioengineered skin constructs based on mesenchymal stromal cells and acellular dermal matrix exposed to inflammatory microenvironment releasing growth factors involved in skin repair.Stem cell research & therapy · 2023Article
- Why Are There So Few FDA-Approved Therapeutics for Wound Healing?International journal of molecular sciences · 2023Review
- Two-stage skin grafting using a basic fibroblast growth factor-impregnated artificial dermis.Regenerative therapy · 2022Article
- Wound Healing Driver Gene and Therapeutic Development: Political and Scientific Hurdles.Advances in wound care · 2021Review
- Review
- [Research progress in adipose tissue promoted wound healing].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2019Review
- Allogeneic mesenchymal stem cells improve the wound healing process of sheep skin.BMC veterinary research · 2018Article
- Monotropein promotes angiogenesis and inhibits oxidative stress-induced autophagy in endothelial progenitor cells to accelerate wound healing.Journal of cellular and molecular medicine · 2018Article
- Asperosaponin VI promotes angiogenesis and accelerates wound healing in rats via up-regulating HIF-1α/VEGF signaling.Acta pharmacologica Sinica · 2018Article
- Mesenchymal Stem Cells in Chronic Wounds: The Spectrum from Basic to Advanced Therapy.Advances in wound care · 2016Review
- Optimal amount of basic fibroblast growth factor in gelatin sponges incorporating β-tricalcium phosphate with chondrocytes.Tissue engineering. Part A · 2015Article
- Wound repair and regeneration: mechanisms, signaling, and translation.Science translational medicine · 2014Review
- Adipokine concentrations in lipoaspirates may have a role in wound healing.Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic skin ulcers such as diabetic ulcers and venous leg ulcers are increasing and are a costly problem in health care. We have developed a novel artificial dermis, collagen/gelatin sponge (CGS), that is capable of the sustained release of basic fibroblast growth factor (bFGF) for more than 10 days. The objective of this study was to investigate the safety and efficacy of CGS impregnated with bFGF in the treatment of chronic skin ulcers. Methods/
designSeventeen patients (≥ 20 years of age) with chronic skin ulcers that have not healed by conventional therapy for at least 4 weeks are being recruited. Patients will be applied with CGS impregnated with bFGF of 7 μg/cm(2) or 14 μg/cm(2) after debridement, and the wound bed improvement will be assessed 14 days after application. "Wound bed improvement" is defined as a granulated and epithelialized area on Day 14 in proportion to the baseline wound area after debridement of 50% or higher. Patients will be followed up until 28 days after application to observe the adverse events related to the application of CGS.
conclusionThis study has been designed to address the safety and efficacy of CGS impregnated with bFGF. If successful, this intervention may be an alternative to bioengineered skin substitutes and lead to substantial and important changes in the management of chronic skin ulcers such as diabetic ulcers and venous ulcers.
Indexed as
Identifiers
22347522PMC3276377W80635809What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.